Onco Actu du 27 mai 2015

	2.7 Etiologie - Obésité
Obesity in teen boys may increase bowel cancer risk in later life [NHS Choices] The very large size of this study is its main strength, along with the fact that BMI was objectively measured by a nurse, and that the national cancer registry in Sweden is estimated to record virtually all cancer cases.
	3. Prévention
Mediterranean-style diet may halve womb cancer risk, study suggests [The Guardian] Julie Sharp, head of health information at Cancer Research UK, said: “While we know that getting older and being overweight both increase a woman’s risk of womb cancer, the idea that a Mediterranean diet could help reduce the risk needs more research. This is partly because the study was based on people remembering what they had eaten in the past”.
	4.5 Dép., diag. & prono. - Colorectal
Doctors’ lapse may explain some minority lag in colon cancer screens [Reuters] Racial minorities may be more likely to forego colon cancer screening than whites because their healthcare providers don’t recommend the potentially life-saving tests, a new study in California suggests.
	5. Traitements
World first as viral immunotherapy for skin cancer shows patient benefit in Phase III trial [The Institute of Cancer Research] Some 16.3% of the group given Talimogene Laherparepvec – known as T-VEC – showed a durable treatment response of more than six months, compared with 2.1% given the control treatment.
MRNAs produced only in ovarian cancer cells discovered [UT SanDiego] The discovery of six isoforms of messenger RNA specific to ovarian cancer could also lead to new therapies, the researchers say in a study published Monday in the Proceedings of the National Academy of Sciences.
Skin cancer patients successfully treated with herpes-based drug [The Guardian] The findings mark the first positive phase 3 trial results for cancer “virotherapy”, where one disease is harnessed and used to attack another.
Genetically engineered virus 'cures' patients of skin cancer [The Telegraph] The therapy – called T-VEC - works by infecting and killing cancer cells while also sparking the immune system into action against tumours.
	5.2 Pharma
Sanofi’s Global Head for Prostate Drug, Zhen Su, Leaves Company [Bloomberg] Zhen Su will pursue a career development opportunity outside of Sanofi and is leaving today, according to an automated reply received in response to an e-mail. Press representatives didn’t respond to repeated attempts for comment.
	5.2.1 Pharma - Partenariats
Bluebird Adds to CAR-T Arsenal With Five Prime Antibody Deal [Xconomy] The parties declined to name the protein or say which tumor types feature the protein, but Five Prime chief business officer Aron Knickerbocker said Five Prime discovered it and thought it would be “well suited” to attack with a CAR-T approach.
bluebird bio and Five Prime Therapeutics Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy [Five Prime] Under the terms of the agreement, Five Prime will provide bluebird bio exclusive rights to its novel human antibodies to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.
	5.3.4 Traitements - AMM (FDA, EMA)
Janssen Receives Positive CHMP Opinion Recommending IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia [Johnson & Johnson] If approved by the European Commission, IMBRUVICA would become the first approved treatment for WM across the EU. It has also recently been approved in WM by the U.S. FDA.
	5.4 Traitements - Economie
Sanofi prostate cancer drug to remain on CDF [Pharmafile] It is not the only drug to get a second chance on the CDF. Last week Bayer won its appeal to keep its stomach tumour drug Stivarga (regorafenib) on the list, although Eisai’s breast cancer medicine Halaven (eribulin) and Lilly’s lung cancer treatment Alimta (pemetrexed) lost similar appeals at the same time.
Big Bets on Proton Therapy Face Uncertain Future [Wall Street Journal] Proton-beam therapy, a highly precise form of radiation, has been dogged by a lack of evidence that it is better than traditional radiation despite costing significantly more.
New Push Ties Cost of Drugs to How Well They Work [Wall Street Journal] The effort is part of a growing push for so-called pay-for-performance deals amid complaints about the rising price of medications, some of which cost more than $100,000 per patient a year.
	5.5 ASCO
Visit the CancerLinQ™ Booth at ASCO’s Annual Meeting to View the System’s First-Ever Demonstration [ASCO] At this year’s Annual Meeting, attendees can view the first-ever demonstration of the CancerLinQ system to learn how it will actually work to revolutionize the second opinion, reveal new possibilities and improve the quality of care.
	5.5.1 ASCO (général)
June 1 Press Briefing at ASCO Annual Meeting to Announce Innovations in Precision Medicine for the 21st Century [ASCO] New developments in clinical trials and health information technology that will improve targeted therapies for patients with cancer will be announced. The briefing will feature three key initiatives designed to advance precision medicine in the 21st Century.
	5.5.10 ASCO (hémato)
51st Annual Meeting of the American Society of Clinical Oncology (ASCO) [Erytech] An oral presentation will be made: Clinical activity of ERY001 (erythrocyte encapsulated l-asparaginase) and native l-asparaginase (L-ASP) in combination with COOPRALL regimen in Phase III randomized trial in patients with relapsed acute lymphoblastic leukemia (ALL).
	5.5.11 ASCO (SNC]
NewLink Genetics to Present Poster on Indoximod, an IDO Pathway Inhibitor, at American Society of Clinical Oncology (ASCO) Annual Meeting [NewLing Genetics] A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component.
	6. Lutte contre les cancers
Complexities of Cancer Explained for Patient Benefit [CANCER RESEARCH Catalyst] We asked Eric Winer to explain for patients and their loved ones how the complexities of cancer make it a hard disease to treat successfully and to talk about efforts to overcome these complexities to reduce the burden of cancer.
	6.1 Observation
Family history may not impact breast cancer survival odds [Reuters] Cutress and colleagues studied 2,850 women diagnosed with breast cancer by age 40 at 127 hospitals in the UK from 2000 to 2008. Half of the women were followed for at least six years. Two-thirds of the women reported no family history of breast cancer. Half of the women were at least 36 years old at the start of the study.
	6.11 Patients
Welcome to the revolution! The changing role of patient advocates within research [Cancer World] Patient advocates believe their input into guiding the research process is key to ensuring the right questions are investigated in the right way. Where it's been successfully tried, both sides agree there is no going back.
	6.5 Médecines alternatives
Younger cancer patients more open to alternative therapies [Reuters] Another drawback of the study is that it didn’t distinguish between alternative medicine, approaches that lack any evidence of effectiveness, and complimentary therapies that have been found to relieve symptoms, said Barrie Cassileth, founding chief of the integrative medicine program at Memorial Sloan Kettering Cancer Center in New York.
	6.7 DMP, Big Data & applis
Tech Rivalries Impede Digital Medical Record Sharing [NY Times] Some tech companies, hospitals and laboratories are intentionally blocking the electronic exchange of health information because they fear that they will lose business if they share information on patients with competing providers, administration officials said.
Books: Review: ‘The Digital Doctor’ by Robert Wachter Weighs Medicine’s Technological Transformation [NY Times] Dr. Wachter is unusual for his equipoise. He is old enough to remember the way things used to work (or fail to work), young enough to be reasonably technology friendly.